Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,929.97 +109.55 (+0.18%) CMC Crypto 200
1,261.42 -96.59 (-7.11%)
ALIM Jul 2024 5.000 put
| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 0.8000 |
| Ask | 2.4500 |
| Strike | 5.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.5500 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GlobeNewswireAlimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA. from May 5 - 9 and Retina Worl
- GlobeNewswire
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the sam
- GlobeNewswire
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of (i) Mr. Todd Wood as President of U.S. Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial
